Entrada Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.8%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$3.79next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 2026 and Full Year 2026 Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly254.9MTarget: Sufficient to fund operations into Q3 2027
Quarterly Net Loss Quarterly-39.7MTarget: Narrowing loss through disciplined expense management
Collaboration Revenue Quarterly900KTarget: Variable based on milestone achievements and partnerships
Watch Items
- ELEVATE-44-201 Cohort 2 (12 mg/kg) Dosing and ReadoutTrigger: Dystrophin and functional data expected by year-end 2026Action: Evaluate safety profile and dystrophin expression levels to validate dose-response modeling.
- ELEVATE-45-201 Cohort 1 (5 mg/kg) Clinical ReadoutTrigger: Data expected mid-2026Action: Assess safety, tolerability, and initial exon 45 skipping efficacy.
- ENTR-601-50 Regulatory Filings in the EUTrigger: Submission expected in H2 2026Action: Monitor regulatory feedback and prepare for study initiation by year-end 2026.
- VX-670 MAD Cohort Enrollment (Vertex Partnership)Trigger: Enrollment and dosing completion expected in H1 2026Action: Review safety and efficacy data updates from partner Vertex.
Research as of 19 Jun 2026